294 related articles for article (PubMed ID: 23009177)
1. Toxic epidermal necrolysis, DRESS, AGEP: do overlap cases exist?
Bouvresse S; Valeyrie-Allanore L; Ortonne N; Konstantinou MP; Kardaun SH; Bagot M; Wolkenstein P; Roujeau JC
Orphanet J Rare Dis; 2012 Sep; 7():72. PubMed ID: 23009177
[TBL] [Abstract][Full Text] [Related]
2. A retrospective, 5-year, clinicoepidemiological study of severe cutaneous adverse reactions (SCARs).
Singh GK; Mitra B; Arora S; Akhoon N; Verma R; Sharma P; Mitra D
Int J Dermatol; 2021 May; 60(5):579-588. PubMed ID: 33454956
[TBL] [Abstract][Full Text] [Related]
3. Severe cutaneous adverse reactions: A 5-year retrospective study at Hospital Melaka, Malaysia, from December 2014 to February 2020.
Tee CT; Abdullah NH; Kristummoonthy P; Lee CS
Med J Malaysia; 2022 Jul; 77(4):409-414. PubMed ID: 35902928
[TBL] [Abstract][Full Text] [Related]
4. A 10-years retrospective study on Severe Cutaneous Adverse Reactions (SCARs) in a tertiary hospital in Penang, Malaysia.
Loo CH; Tan WC; Khor YH; Chan LC
Med J Malaysia; 2018 Apr; 73(2):73-77. PubMed ID: 29703869
[TBL] [Abstract][Full Text] [Related]
5. Severe Cutaneous Adverse Drug Reactions at a Tertiary Care Center in Saudi Arabia.
AlJasser MI
Dermatol Res Pract; 2023; 2023():8928198. PubMed ID: 37206671
[TBL] [Abstract][Full Text] [Related]
6. Rare and Complicated Overlap of Stevens-Johnson Syndrome and Acute Generalized Exanthematous Pustulosis.
Chowdhury TA; Talib KA; Patricia J; Nye KD; Moosa SA
Cureus; 2021 Jun; 13(6):e15921. PubMed ID: 34336425
[TBL] [Abstract][Full Text] [Related]
7. Overlapping DRESS and Stevens-Johnson Syndrome: Case Report and Review of the Literature.
Casagranda A; Suppa M; Dehavay F; Del Marmol V
Case Rep Dermatol; 2017; 9(2):1-7. PubMed ID: 28611628
[TBL] [Abstract][Full Text] [Related]
8. Systematic review of BRAF/MEK inhibitors-induced Severe Cutaneous Adverse Reactions (SCARs).
Torres-Navarro I; de Unamuno-Bustos B; Botella-Estrada R
J Eur Acad Dermatol Venereol; 2021 Mar; 35(3):607-614. PubMed ID: 32846030
[TBL] [Abstract][Full Text] [Related]
9. Severe flucloxacillin-induced acute generalized exanthematous pustulosis (AGEP), with toxic epidermal necrolysis (TEN)-like features: does overlap between AGEP and TEN exist? Clinical report and review of the literature.
van Hattem S; Beerthuizen GI; Kardaun SH
Br J Dermatol; 2014 Dec; 171(6):1539-45. PubMed ID: 24888401
[TBL] [Abstract][Full Text] [Related]
10. The Role of Frozen Section in the Rapid Diagnosis of Severe Cutaneous Adverse Drug Reactions.
Nicholas R; Bindra MS; Mathew L; Sathishkumar D; Lakshmanan J; George R
Indian Dermatol Online J; 2021; 12(1):78-83. PubMed ID: 33768026
[TBL] [Abstract][Full Text] [Related]
11. Aetiopathogenesis of severe cutaneous adverse reactions (SCARs) in children: A 9-year experience in a tertiary care paediatric hospital setting.
Liccioli G; Mori F; Parronchi P; Capone M; Fili L; Barni S; Sarti L; Giovannini M; Resti M; Novembre EM
Clin Exp Allergy; 2020 Jan; 50(1):61-73. PubMed ID: 31608511
[TBL] [Abstract][Full Text] [Related]
12. Paracetamol (Acetaminophen)-associated SJS, TEN, AGEP, and DRESS Syndromes - A Narrative Review.
Pakkir Maideen NM; Barakat IR; Jumale AH
Curr Drug Saf; 2024; 19(2):218-223. PubMed ID: 37151075
[TBL] [Abstract][Full Text] [Related]
13. Severe cutaneous adverse reactions related to systemic antibiotics.
Lin YF; Yang CH; Sindy H; Lin JY; Rosaline Hui CY; Tsai YC; Wu TS; Huang CT; Kao KC; Hu HC; Chiu CH; Hung SI; Chung WH
Clin Infect Dis; 2014 May; 58(10):1377-85. PubMed ID: 24599767
[TBL] [Abstract][Full Text] [Related]
14. Clinical features and prognostic factors of severe cutaneous adverse drug reactions: A single-center retrospective study of 209 cases in China.
Deng M; Su Y; Wu R; Li S; Tang G; Kuang Q; Luo X; Zhu Y; Shen W
Int Immunopharmacol; 2023 Jan; 114():109530. PubMed ID: 36508915
[TBL] [Abstract][Full Text] [Related]
15. A multicentre study to determine the value and safety of drug patch tests for the three main classes of severe cutaneous adverse drug reactions.
Barbaud A; Collet E; Milpied B; Assier H; Staumont D; Avenel-Audran M; Grange A; Amarger S; Girardin P; Guinnepain MT; Truchetet F; Lasek A; Waton J;
Br J Dermatol; 2013 Mar; 168(3):555-62. PubMed ID: 23136927
[TBL] [Abstract][Full Text] [Related]
16. Drug-induced severe cutaneous adverse reactions: Determine the cause and prevention.
Zhang C; Van DN; Hieu C; Craig T
Ann Allergy Asthma Immunol; 2019 Nov; 123(5):483-487. PubMed ID: 31400461
[TBL] [Abstract][Full Text] [Related]
17. Severe cutaneous adverse reactions associated with the immune checkpoint inhibitors: A case/non-case analysis using the Food and Drug Administration Adverse Event Reporting System.
Godfrey H; Jedlowski P; Thiede R
Australas J Dermatol; 2024 May; 65(3):243-253. PubMed ID: 38572842
[TBL] [Abstract][Full Text] [Related]
18. Severe cutaneous adverse drug reactions: incidence, clinical characteristics, treatment, and outcome in pediatric patients.
Na Bangxang P; Wisuthsarewong W; Nitiyarom R
Asian Pac J Allergy Immunol; 2024 Jan; ():. PubMed ID: 38183639
[TBL] [Abstract][Full Text] [Related]
19. Analysis of severe cutaneous adverse reactions (SCARs) in Taiwan drug-injury relief system: 18-year results.
Huang PW; Chiou MH; Chien MY; Chen WW; Chu CY
J Formos Med Assoc; 2022 Aug; 121(8):1397-1405. PubMed ID: 34674904
[TBL] [Abstract][Full Text] [Related]
20. An exploratory factor analysis of the spontaneous reporting of severe cutaneous adverse reactions.
Hauben M; Hung E; Hsieh WY
Ther Adv Drug Saf; 2017 Jan; 8(1):4-16. PubMed ID: 28203363
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
